Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (11-20 of 466) with videos related to

Pageof 47
Sort By:
Current Oncology Reports|February 7, 2020
Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment ParadigmAnnika Scheffold, Stephan Stilgenbauer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?Daniel Mertens, Stephan Stilgenbauer
Blood|March 31, 2012
CLL and deletion 13q14: merely the miRs?Daniel Mertens, Stephan Stilgenbauer
Oncotarget|February 15, 2011
Refractory chronic lymphocytic leukemia--new therapeutic strategiesAndrea Schnaiter, Stephan Stilgenbauer
Blood|August 14, 2010
CLL 17p deletion: more than 'miR'ly p53?Thorsten Zenz, Stephan Stilgenbauer
Blood|March 18, 2017
Ibrutinib-resistant CLL: unwanted and unwonted!Daniel Mertens, Stephan Stilgenbauer
Therapeutic Advances in Hematology|April 5, 2013
Novel targeted treatment strategies for refractory chronic lymphocytic leukaemiaAndrea Schnaiter, Stephan Stilgenbauer
Hematology/Oncology Clinics of North America|April 9, 2013
17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approachAndrea Schnaiter, Stephan Stilgenbauer
Haematologica|February 2, 2020
<i>BIRC3</i> mutations in chronic lymphocytic leukemia - uncommon and unfavorableEugen Tausch, Stephan Stilgenbauer
Haematologica|November 1, 2019
Response to Comment by Jonathan Weiss <i>et al.</i>Eugen Tausch, Stephan Stilgenbauer
Pageof 47

Showing results (11-20 of 466) with videos related to

Sort By:
Pageof 47
Current Oncology Reports|February 7, 2020
Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment ParadigmAnnika Scheffold, Stephan Stilgenbauer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?Daniel Mertens, Stephan Stilgenbauer
Blood|March 31, 2012
CLL and deletion 13q14: merely the miRs?Daniel Mertens, Stephan Stilgenbauer
Oncotarget|February 15, 2011
Refractory chronic lymphocytic leukemia--new therapeutic strategiesAndrea Schnaiter, Stephan Stilgenbauer
Blood|August 14, 2010
CLL 17p deletion: more than 'miR'ly p53?Thorsten Zenz, Stephan Stilgenbauer
Blood|March 18, 2017
Ibrutinib-resistant CLL: unwanted and unwonted!Daniel Mertens, Stephan Stilgenbauer
Therapeutic Advances in Hematology|April 5, 2013
Novel targeted treatment strategies for refractory chronic lymphocytic leukaemiaAndrea Schnaiter, Stephan Stilgenbauer
Hematology/Oncology Clinics of North America|April 9, 2013
17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approachAndrea Schnaiter, Stephan Stilgenbauer
Haematologica|February 2, 2020
<i>BIRC3</i> mutations in chronic lymphocytic leukemia - uncommon and unfavorableEugen Tausch, Stephan Stilgenbauer
Haematologica|November 1, 2019
Response to Comment by Jonathan Weiss <i>et al.</i>Eugen Tausch, Stephan Stilgenbauer
Pageof 47